psychedelics


Silo Wellness Issues Shareholder Letter and Announces New Chief Executive Officer

June 9th, 2022 - Ryan Allway

Toronto, Ontario–(Newsfile Corp. – June 9, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company“), a leading global psychedelics company, announced today that Silo Wellness founder and chairman of the board of directors Mike Arnold is assuming the role of the Company’s interim chief executive officer to continue […]

Nirvana Life Sciences Announces Positive Results for Addiction Relapse Prevention from Their Latest Pre-Clinical Psychedelic Drug Study

June 2nd, 2022 - Ryan Allway

Psilocybin reduced reinstatement of Heroin seeking behavior when administered immediately after a memory retrieval task in rats.   VANCOUVER, BC, June 2, 2022 /CNW/ – Nirvana Life Sciences Inc. (Nirvana or the “Company”) (CSE: NIRV),  a Canadian based life sciences company focused on developing novel therapeutic products derived from psychedelics to produce non-addictive solutions for opioid addiction […]

LFTD Partners Inc. Reports QoQ Revenue Up 41%, Net Income Up 118%, and Diluted EPS up 125% During Q1 2022

May 12th, 2022 - Ryan Allway

JACKSONVILLE, FL / ACCESSWIRE / May 12, 2022 / LFTD Partners Inc. (“LFTD Partners” or the “Company”) (OTCQB:LIFD), the corporate parent of leading cannabis and psychedelics-lifestyle and consumer packaged goods manufacturer Lifted Made, today announced record quarterly revenue, net income, and diluted earnings per share for Q1 2022. Financial Highlights – Q1 2022 compared to Q4 2021 […]

Company Leverages Household Brand Status in Effort to be World’s Largest Chain of Psychedelic Mental Health Clinics

April 18th, 2022 - Ryan Allway

LOS ANGELES, April 18, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) announced today it has taken the next step in the execution of its ketamine clinic roll-up strategy – a move the Company says is motivated by an intention to become the world’s largest chain of psychedelic […]

Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

March 31st, 2022 - Ryan Allway

TORONTO–(BUSINESS WIRE)– Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that the first study visit has been conducted in a Cybin-sponsored feasibility study evaluating Kernel’s quantitative neuroimaging technology, Flow, to measure ketamine’s psychedelic effects on cerebral cortex hemodynamics.   “The commencement of the Kernel feasibility study marks […]

Revitalist Increases Clinic Count to 10 with the Acquisition of a Virginia Ketamine Clinic

March 29th, 2022 - Ryan Allway

VANCOUVER, British Columbia, March 29, 2022–(BUSINESS WIRE)–REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company“) (CSE: CALM) (CSNX: CALM.CN) (OTC: RVLWF) is pleased to announce that has it has entered into a definitive agreement (“Merger Agreement“) to acquire Alchemy Wellness (“Alchemy“) a ketamine clinic (“Acquisition“) located in Richmond, Virginia (“Virginia Clinic“). The Acquisition, which was previously […]

Core One Labs’ Akome Biotech Initiates Neurogenesis Stimulation and Modeling Studies: Advancing its Proprietary Psychedelic-based Pharmaceutical Formulations

March 4th, 2022 - Ryan Allway

VANCOUVER, British Columbia, March 04, 2022 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”), has entered into an agreement with the Universidad Complutense de Madrid (“Universidad Complutense”), officially commencing neurogenesis stimulation and modeling studies research, […]

Wellbeing Digital Sciences Subsidiary IRP Health Receives Approval From Veterans Affairs Canada for Reactivation Program

March 3rd, 2022 - Ryan Allway

The Company’s Receipt of Approval for the Multidisciplinary “Reactivation” Program Designed by its Wholly Owned Subsidiary is a Major Milestone That is Expected to Benefit Veterans and First Responders for the Foreseeable Future   VANCOUVER, British Columbia, March 03, 2022 (GLOBE NEWSWIRE) — Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: […]

Incannex Executes License Agreement with Monash University to Develop a Combination Treatment Using Virtual Reality and Psychedelics

March 3rd, 2022 - Ryan Allway

MELBOURNE, Australia, March 3, 2022 /PRNewswire/ — Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for unmet medical needs, today announced it has executed a license agreement with Monash University (‘Monash University’ or ‘Monash’) to develop a novel treatment that combines Virtual […]

Revitalist and PharmaTher Announce Collaboration to Develop and Advance Novel and Standardized Ketamine Treatment Protocols for Mental Health Disorders and Chronic Pain Syndromes

March 1st, 2022 - Ryan Allway

REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) is pleased to announce its collaboration with PharmaTher Holdings Ltd. (“PharmaTher”) (CSE: PHRM) (OTCQB: PHRM), a leader in specialty ketamine pharmaceuticals, by creating strategic opportunities to develop and advance novel and standardized treatment protocols with ketamine for individuals suffering from […]

Silo Wellness Announces Successful Launch of 2022 Psilocybin Retreat Schedule and other Corporate Updates

February 23rd, 2022 - Ryan Allway

Toronto, Ontario–(Newsfile Corp. – February 23, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company”), a leading global psychedelics company, today announces several corporate updates. On February 4, 2022, the Company completed its first Jamaican psilocybin retreat of 2022 entitled “Renew Your Purpose” (see press release of December […]

Enveric Biosciences Announces Pricing of $10 Million Public Offering

February 11th, 2022 - Ryan Allway

NAPLES, Fla., Feb. 11, 2022 /PRNewswire/ – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience company developing next-generation, psychedelic-inspired mental health and oncology treatments, today announced the pricing of its previously announced underwritten public offering of 20,000,000 shares of its common stock and warrants to purchase up to 20,000,000 shares of its common stock. Each […]

Clearmind Medicine Secures CAD$1.6 Million in Private Placement

February 8th, 2022 - Ryan Allway

Clearmind and Medigus, the investor, intend to form a joint venture in the field of food industry, based on Clearmind’s unique psychedelics IP   TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTCMKTS: CMNDF) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived […]

Entheon Biomedical Announces the Approval of DMT Clinical Trial

February 3rd, 2022 - Ryan Allway

Vancouver, British Columbia–(Newsfile Corp. – February 03, 2022) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, announced today the approval by the local Dutch ethics committee of […]

Revitalist Executes on Mission to Build a National Network of Ketamine Clinics

January 28th, 2022 - Ryan Allway

Psychedelics have shown tremendous promise in treating depression, anxiety, post-traumatic stress disorder, and a range of other mental health conditions. In particular, assisted psychotherapy combines psychedelic substances with talk therapy to facilitate breakthroughs and help patients that don’t see relief through conventional treatments. While psilocybin, MDMA, and other psychedelic medicines remain in clinical trials, the […]

Psychedelic Science Leader Eleusis to Become Public Company in Merger with Silver Spike Acquisition Corp. II

January 20th, 2022 - Ryan Allway

Business combination with Silver Spike Acquisition Corp. II (Nasdaq: SPKB) expected to generate gross proceeds of up to $288 million and implies a combined enterprise value of $446 million Eleusis pioneers the development of psychedelic drug candidates in the life sciences space, with the goal of transforming psychedelics into broadly accessible medicines Eleusis designed ELE-Psilo, […]

Psychedelic Science Leader Eleusis to Become Public Company in Merger with Silver Spike Acquisition Corp. II

January 20th, 2022 - Ryan Allway

Business combination with Silver Spike Acquisition Corp. II (Nasdaq: SPKB) expected to generate gross proceeds of up to $288 million and implies a combined enterprise value of $446 million Eleusis pioneers the development of psychedelic drug candidates in the life sciences space, with the goal of transforming psychedelics into broadly accessible medicines Eleusis designed ELE-Psilo, […]

Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy to Patients under Health Canada’s Special Access Program

January 18th, 2022 - Ryan Allway

Under Mydecine’s recently announced Special Access Support and Supply Program, the Company will supply cGMP Psilocybin and MDMA to The Newly. The companies will partner to co-develop protocols, therapy manuals, and training needed to treat patients who need specific care.   VANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) […]

SciSparc Exploring Psychedelics as Possible Avenue to Expand Its IP Portfolio

January 11th, 2022 - Ryan Allway

TEL AVIV, Israel, Jan. 11, 2022 /PRNewswire/ — SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company”), announced that it has begun to examine the possibility of including psychedelic compounds as potential drug candidates for its intellectual property portfolio.     […]

Clearmind Medicine Strengthens Presence in North America with New Senior Appointments

January 11th, 2022 - Ryan Allway

Mr. Mark Haden appointed to VP Business Development and Mr. Gilad Babchuk as Head of Strategy and Communication   TORONTO, Jan. 11, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread […]

Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain

January 11th, 2022 - Ryan Allway

-Enrollment expected to begin in early 2022 – TORONTO, January 11, 2022–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™“, today announced that an Institutional Review Board (“IRB”) has approved a Company-sponsored feasibility study using Kernel’s quantitative neuroimaging technology, Kernel Flow, to measure ketamine’s psychedelic effect […]

Clearmind Medicine Establishes Third R&D Partnership With the Hebrew University

January 10th, 2022 - Ryan Allway

Research will focus on developing novel patentable psychedelics as potential drug candidates   TORONTO, Jan. 10, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the “Company”), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased […]

PharmAla Biotech Announces Listing on the Canadian Securities Exchange

January 10th, 2022 - Ryan Allway

VANCOUVER, January 10, 2022 (GLOBE NEWSWIRE) – PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA), a biotech company focused on the research, development and manufacturing of “psychedelic” pharmaceuticals in the MDXX class, is pleased to announce that the Company’s common shares have been approved for listing on the Canadian Securities Exchange (the “CSE”) […]

3 Ways to Invest in Ketamine Clinics

January 6th, 2022 - Ryan Allway

Researchers believe that psychedelics may revolutionize mental health treatments, but FDA-approved psychedelics remain out of reach—with one exception. Unlike psilocybin or MDMA, ketamine is FDA-approved for anesthesia during medical procedures, opening the door to off-label use as a treatment for depression and other mental illnesses. With the FDA’s approval of Spravato and a growing body […]

Silo Wellness Appoints CEO Douglas K. Gordon to Board of Directors and Provides Corporation Updates

January 6th, 2022 - Ryan Allway

Toronto, Ontario–(Newsfile Corp. – January 6, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company“), a leading global psychedelics company, is pleased to announce that the Company’s Chief Executive Officer, Douglas K. Gordon, has been appointed as a director of the company. Mr. Gordon has led the company […]

Entheon Biomedical Announces EEG Patent Application & Provides Research Update

December 16th, 2021 - Ryan Allway

Vancouver, British Columbia–(Newsfile Corp. – December 16, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to provide an update on its patent portfolio as […]

MINDCURE Appoints Dr. Doron Sagman as Chief Medical Officer

December 14th, 2021 - Ryan Allway

VANCOUVER, BC, Dec. 14, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics, announces the appointment of Doron Sagman, MD, FRCPC, as the Company’s new Chief Medical Officer (“CMO”). Dr. Joel Raskin who was acting CMO will transition into an advisory role […]

Revitalist Executes on Vision to Become a Clinical Leader in Psychedelics

December 10th, 2021 - Ryan Allway

Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) set out to build a nationwide network of psychedelic-assisted psychotherapy clinics in 2018. Since then, the company has grown its footprint to ten clinics across six states exceeding 60,650 sq. ft. of space and clinical capacity for more than 120 treatment rooms, with more […]

Jupiter Wellness Signs Definitive Agreement to Merge with Next Frontier Pharmaceuticals, a Leading Drug Developer and Manufacturer of Synthetic Cannabinoid Pharmaceuticals

December 9th, 2021 - Ryan Allway

Owner of SYNDROS®(dronabinol), the only US-based FDA approved CII Tetrahydrocannabinol (THC), a liquid cannabinoid used in adults to treat: Chemotherapy Induced Nausea and Vomiting (CINV) associated in adult patients who have failed to respond adequately to conventional antiemetic treatments; and Anorexia associated with weight loss in adult patients with Acquired Immune Deficiency Syndrome (AIDS) 83,000 […]

Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2

December 8th, 2021 - Ryan Allway

VANCOUVER, British Columbia, Dec. 08, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical development company is pleased to announce that it has completed the manufacturing of its clinical grade supply (“cGMP”) of AP-188 (“N,N-Dimethyltryptamine or DMT”) at Canadian manufacturer Dalton Pharma Services. […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading